Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑oxo‑2‑[(4‑phenylphenyl)sulfonylamino]ethanamide is an experimental small molecule inhibitor of matrix metalloproteinase‑12 (MMP‑12), also known as macrophage metalloelastase. It belongs to the biphenyl class of organic compounds and has a molecular formula of C14H12N2O4S. The compound has been studied primarily as a discovery agent and is not approved for clinical use in any indication. Its mechanism involves inhibition of MMP‑12, an enzyme implicated in extracellular matrix degradation and various inflammatory processes[1][5]. No clinical trials or approved indications are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide.